Claiborne Cary J has filed 6 insider transactions across 2 companies since May 2023.
Most recent transaction: a grant/award of 138000 shares of ADIAL PHARMACEUTICALS, INC. ($ADIL) on May 29, 2025.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 29, 2025 | ADIAL PHARMACEUTICALS, INC. | $ADIL | Claiborne Cary J | Chief Executive Officer | A | Stock Option (Right to Buy) | 138000 | $0.00 | 138,000.0000 | 6,539,760 | 9999.99% | 2.11% |
| Dec. 5, 2024 | ADIAL PHARMACEUTICALS, INC. | $ADIL | Claiborne Cary J | Chief Executive Officer | A | Stock Option (Right to Buy) | 350000 | $0.00 | 350,000.0000 | 5,835,682 | 9999.99% | 6.00% |
| March 25, 2024 | ADIAL PHARMACEUTICALS, INC. | $ADIL | Claiborne Cary J | Chief Executive Officer | A | Stock Option (Right to Buy) | 60000 | $0.00 | 60,000.0000 | 1,424,661 | 9999.99% | 4.21% |
| Jan. 15, 2024 | LadRx Corp | $LADX | Claiborne Cary J | Director | A | Stock Option (Right to Buy) | 5000 | $0.00 | 5,000.0000 | 0 | 9999.99% | 0.00% |
| May 23, 2023 | ADIAL PHARMACEUTICALS, INC. | $ADIL | Claiborne Cary J | Chief Executive Officer | A | Common Stock | 420000 | $0.00 | 1,520,000.0000 | 26,463,559 | 38.18% | 1.59% |
| May 23, 2023 | ADIAL PHARMACEUTICALS, INC. | $ADIL | Claiborne Cary J | Chief Executive Officer | A | Stock Option (Right to Buy) | 300000 | $0.00 | 300,000.0000 | 26,463,559 | 9999.99% | 1.13% |